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Hormaomycin (HRM) is a structurally remarkable
peptide produced by Streptomyces griseoflavus
W-384 that acts as a Streptomyces signaling
metabolite and exhibits potent antibiotic activity
against coryneform actinomycetes. HRM biosyn-
thetic studies have been hampered by inconsistent
and low production. To enhance fermentation titers,
the role of its cluster-encoded regulatory genes
was investigated. Extra copies of the putative
regulators hrmA and hrmB were introduced into the
wild-type strain, resulting in an increase of HRM
production and its analogs up to 135-fold. For the
HrmB overproducer, six bioactive analogs were iso-
lated and characterized. This study demonstrates
that HrmA and HrmB are positive regulators in HRM
biosynthesis. A third gene, hrmH, was identified as
encoding a protein capable of shifting the metabolic
profile of HRM and its derivatives. Its manipulation
resulted in the generation of an additional HRM
analog.
INTRODUCTION
Gram-positive soil-dwelling Streptomyces spp. bacteria are pro-
lific producers of secondary metabolites that are sometimes
used as antibiotics in medicine, agriculture, and food industries
(Challis and Hopwood, 2003; Chen et al., 2010). An example
of the biosynthetic sophistication found in this genus is the
depsipeptide hormaomycin (HRM), also known as takaokamycin
(Omura et al., 1984). HRM, isolated from Streptomyces griseofla-
vusW-384, exhibits an extraordinary structure containing almost
exclusively nonproteinogenic building blocks, several of which
carry chloro, nitro, and cyclopropyl moieties (Andres et al.,
1989; Ro¨ssner et al., 1990; Figure 1). 3-(trans-20-nitrocyclo-
propyl)alanine ([3-Ncp]Ala) and 4-(Z)-propenylproline ([4-Pe]
Pro) are unusual building blocks to HRM. In addition, HRM
belongs to the few known signaling metabolites that induce
aerial mycelium formation and stimulation of antibiotic produc-
tion in other Streptomyces species (Andres et al., 1990). Addi-
tionally, it is a narrow-spectrum antibiotic with best activities inChemistry & Biology 20,the picomolar range against Arthrobacter spp. (Andres et al.,
1990) and possesses in vitro activity against the malaria path-
ogen Plasmodium falciparum (Otoguro et al., 2003).
Several HRM derivatives have been generated through chem-
ical synthesis and precursor-directed biosynthesis (Zlatopolskiy
et al., 2004, 2006; Reinscheid et al., 2005; Kozhushkov et al.,
2005). Previous work has also provided some insights into the
biosynthesis of the unusual building blocks and has established
that the peptide backbone is assembled by a nonribosomal
peptide synthetase (NRPS) pathway (Kozhushkov et al., 2005;
Ho¨fer et al., 2011; Cru¨semann et al., 2013). However, significant
challenges during studies on the pathway are the low production
titers from S. griseoflavus and the propensity of this bacterium to
lose its biosynthetic capability. The regulation of Streptomyces
natural products is often complex and commonly involves
several layers of pathway-specific and/or global regulators.
Genetic engineering of these regulatory systems is taken as an
approach to increase production titers (Bibb, 2005). Therefore,
we aimed to investigate whether insights into the regulation of
HRM biosynthesis would allow us to create improved HRM pro-
ducers. Because HRM acts as a metabolic and developmental
regulator in Streptomyces spp., an understanding of the factors
governing its production would also be an important basis to un-
ravel the intricate regulatory network in intra- and interspecies
HRM signaling.
Herein, we report the identification by gene knockout, comple-
mentation, and feeding experiments of three regulators that act
at the pathway and subpathway levels. The overexpression of
two activator genes, hrmA and hrmB, yielded stable producers
with greatly increased titers. As a result of upregulation, we
found six cryptic bioactive HRM congeners. Additionally, HrmH
was identified as an unusual regulator affecting the metabolic
profile in HRM biosynthesis. Unexpectedly, manipulation of
hrmH provided a seventh bioactive, but non-natural, analog
that is the probable result of metabolic cross-talk with a non-
HRM pathway within the HRM producer.
RESULTS
The HRM Gene Cluster Contains Three Candidates for
Regulatory Genes
A hallmark of many Streptomyces natural product pathways is
the existence of multiple regulatory genes encoded within their
biosynthetic gene clusters. The recently sequenced HRM gene
cluster contains two large NRPSs and 21 additional putative839–846, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 839
Figure 1. The Structure of HRM
See also Figures S1 and S2 and Tables S1 and S2.
Figure 2. Overexpression of HrmA and HrmB in the WT Strain
HPLC UV traces (273 nm) of S. griseoflaus W-384 WT, HrmA overproducer
(XC1), HrmB overproducer (XC2), and hrmA/hrmB double-expression strain
(XC3). HRM A1–A6 are HRM analogs isolated from XC2.
See also Figure S3 and Table S3.
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Regulation-Guided Formation of HRM Analogsgenes (Ho¨fer et al., 2011), of which hrmA and hrmB were pre-
dicted as positive regulators based on bioinformatic analyses
(Figure S2 available online). HrmA is homologous to transcrip-
tional regulators belonging to the AraC family (Martin and Ros-
ner, 2001), showing 35% protein sequence identity to TxtR, an
AraC/XylS cellobiose-binding protein that induces thaxtomin
production in Streptomyces scabies (Joshi et al., 2007). HrmB
is homologous to a small family of regulators with poorly under-
stood mechanisms that includes NovE, a transcriptional acti-
vator of novobiocin biosynthesis (Dangel et al., 2008), and
LmbU, a positive regulator of lincomycin biosynthesis (Chen
et al., 2011). All three of these homologs contain a TTA codon
for leucine that is rare in streptomycetes and indicates regulation
by the tRNAUUA-encoding gene bldA (Leskiw et al., 1991).
In addition to hrmA and hrmB, hrmH was also tentatively
included in the list of regulatory gene candidates. Homologs of
HrmH belong to the poorly characterized YjgF/Yer057p/UK114
family. Members with known function exhibit diverse and
often regulatory activities. For example, mammalian UK114
( = endoribonuclease L-PSP) is a potent inhibitor of cell-free pro-
tein synthesis by disintegrating polysomes through fragmenta-
tion of polysomal mRNA (Oka et al., 1995; Morishita et al.,
1999), and Salmonella enterica YjgF (RidA) and the human
homolog UK114 inhibit threonine dehydratase-dependent phos-
phoribosylamine formation in vitro, apparently by deaminating a
biosynthetic intermediate (Lambrecht et al., 2010). Because
these homologs can interact with nucleic acids as well as small
molecules, it was not clear at this stage whether HrmH might
be a regulator and/or a biosynthetic enzyme.
Overexpression of Pathway-Specific Activators HrmA
and HrmB Significantly Increases HRM Production
Because hrmA and hrmB were candidates for activator genes,
we investigated whether their overexpression results in a spe-840 Chemistry & Biology 20, 839–846, June 20, 2013 ª2013 Elseviercific increase of HRM production. A copy of hrmA or hrmB was
placed under control of the constitutive ermE* promoter on the
pWHM4*-based (Matseliukh, 2001) vector pXC10 and was indi-
vidually overexpressed in S. griseoflavus W-384. Analysis of the
culture extracts with high-performance liquid chromatography
(HPLC) revealed that HRM production was increased 40-fold in
the hrmA overexpression strain XC1 and 135-fold in the hrmB
overexpression strain XC2 relative to wild-type (WT) (Figure 2).
These results are consistent with a role of both genes as pathway
activators. To test whether the positive regulatory functions act
in an additive way that would allow a further increase in HRM
titers, a hrmA/hrmB double-overexpression strain XC3 was
created; however, analysis of HRM production did not indicate
upregulation beyond the level of the previous best producer
strain XC2. It is noteworthy that analogs HRM A1 and/or HRM
A2 were more highly upregulated in XC3 compared to either
strains XC1 or XC2.
Overexpression of HrmB Results in Six HRM Analogs
Upon closer examination of the HPLC profiles obtained from
the regulatory mutants, we noticed a series of different com-
pounds in all three strains. Initial electrospray ionization-liquid
chromatography-mass spectrometry (ESI-LC-MS) and tandem
mass spectrometry (MS/MS) analyses indicated that they
were structurally related to HRM. A search for their specific
ions in LC-MS runs showed that all but one (HRM A6) was
detectable in the WT strain, albeit in extremely low amounts.
To determine their structures, the peptides produced by the
hrmB overexpression strain XC2 were purified. In total, six
compounds (HRM A1–A6) (Figure 3) were isolated from strain
XC2 and were subsequently characterized with nuclear mag-
netic resonance (NMR) and MS/MS analyses (Figures S4
and S5; Tables S1 and S2). In comparison to HRM, HRM A1
lacks the chlorine moiety in the pyrrole-2-carboxylic acid-type
starter unit, and in HRM A2 a valine residue is incorporated
instead of isoleucine. HRM A3–5 all possess leucine sub-
stitutions for either one or both (3-Ncp)Ala units. SimilarlyLtd All rights reserved
Figure 3. Structures of HRM Analogs HRM A1–6
Absolute configurationswere surmised experimentally through comparisons ofMS andNMRdata with the parent HRMstructure. HRMA4was characterized only
using MS data due to its limited production.
See also Figures S4 and S5 and Tables S1 and S2.
Chemistry & Biology
Regulation-Guided Formation of HRM Analogsas in the D-configured endocyclic (3-Ncp)Ala unit in HRM, NMR
measurements, in conjunction with comparisons to the native
HRM structure, support structures harboring the same stereo-
chemical inversion of leucine in HRM A3 and HRM A5 (Figures
S4C and S4E; Table S2). The unusual product HRM A6 might
be the product of oxidative radical coupling of HRM and ethyl
acetate. Because ethyl acetate was used for extraction, HRM
A6 is likely to be an artifact. In an effort to further enhance pro-
duction of HRM A3–5, leucine was supplemented in cultures of
the hrmB-overproducing strain, resulting in a modest increase
in their titers with a concomitant decrease in HRM production
(Figure S5).
HrmH Influences Product Distribution in HRM
Biosynthesis
To determine the role of the unusual gene hrmH, a hrmH disrup-
tion mutant (DH) was generated by replacement with an apramy-
cin resistance gene cassette via PCR-targeted recombination
(Gust et al., 2003). Unexpectedly, the deletion of hrmH had no
major effect on HRM production relative to the WT. However,
an additional metabolite was observed in the extract of the DH
strain that diminished upon complementation with hrmH on a
plasmid. MS analysis of the HPLC-purified peak revealed a
mass of 1,103.464 Da for the [M+H]+ ion (Figure 4A), which
corresponds to a compound with 26 mass units less thanChemistry & Biology 20,HRM. Based on the molecular formula of C55H69O14N10Cl
for HRM with an exact mass of 1,129.476 Da for [M+H]+, we
estimated the molecular formula of this compound, HRM A7,
as C53H67N10O14Cl with loss of C2H2 (calculated mass
1,103.460 Da for [M+H]+). Because the titers were too low for
NMR analysis, HRM A7 was initially characterized with MS/MS
analysis following isolation by HPLC. All fragmentations of
HRM A7 were consistent with the structure of HRM except for
426.229 [M+Na]+ (Table S1B), corresponding to an altered
HRM tripeptide fragment normally including 3-(2S,3R)-methyl-
phenylalanine ([b-Me]Phe), L-isoleucine, and (4-Pe)Pro. Metha-
nolysis to open the depsipeptide ring followed by MS/MS
analysis of the isolated peak narrowed down the modified frag-
ment to L-isoleucine and (4-Pe)Pro, suggesting that the non-
natural amino acid (4-Pe)Pro was modified in HRM A7.
Based on this hypothesis, a series of feeding studies were
carried out to determine the structure of the incorporated resi-
due. In addition to supplementing fermentations of the WT,
DH, and DH-complement strains with (4-Pe)Pro in control exper-
iments, cultures were fed the commercially available L-pipecolic
acid and (2S,4R)-4-methylpyrrolidine-2-carboxylic acid (trans-
[4-Me]Pro) as precursor amino acid candidates with a matching
mass and known occurrence in nonribosomal peptides (He,
2006; Katz et al., 1977). As shown in Figures 4C and 4D, feeding
with trans-(4-Me)Pro resulted in the appearance of a 10-fold839–846, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 841
Figure 4. Analysis of the HRM Analog HRM A7 in hrmH and hrmD Mutants
(A) MS analysis of HRM A7.
(B) The structure of HRM A7.
(C) Chemical and genetic complementation of the hrmHmutant. HPLC UV traces (273 nm) of S. griseoflavusW-384WT, DH complement (DH/HrmH), DH fed with
pipecolic acid (DH + pipecolic acid), hrmHmutant (DH),DH fed with 4-(Z)-propenylproline (DH + [4-Pe]Pro), andDH fedwith 4-methyl-2-pyrrolidine carboxylic acid
(DH + [4-Me]Pro).
(D) Chemical and genetic complementation of the hrmDmutant. HPLC UV traces (273 nm) of S. griseoflavusW-384WT, DD complement (DD/HrmD), DD fed with
pipecolic acid (DD+pipecolic acid), hrmDmutant (DD),DD fedwith (4-Pe)Pro ([4-Pe]Pro) (DH+ [4-Pe]Pro), andDD fedwith (4-Me)Pro ([4-Me]Pro) (DD+ [4-Me]Pro).
See also Figures S6 and S7 and Tables S1–S3.
Chemistry & Biology
Regulation-Guided Formation of HRM Analogsenhanced peak in the HPLC trace as compared to the unsup-
plemented DH strain, with a retention time and mass spectrum
identical to that of HRM A7. In contrast, feeding of pipecolic
acid did not change the metabolic profile, suggesting that
this compound is not incorporated. As an additional control,
(3-Ncp)Ala was also independently fed into the strains, which
showed no increase in HRM production. To further characterize
the peptide, it was isolated from the trans-(4-Me)Pro enrichment
culture and subjected to NMR analysis. The data confirmed
the presence of a trans-(4-Me)Pro unit in HRM A7 in place of
the (4-Pe)Pro moiety found in HRM (Figures 4B and S5). It should
be noted that other HRM derivatives possessing proline analogs
from the nonsupplemented cultures with the same mass and
exact retention time as HRM A7 would also be consistent with
these data. All in all, these results show that the presence or
absence of HrmH has an effect on the product distribution in
HRM biosynthesis.842 Chemistry & Biology 20, 839–846, June 20, 2013 ª2013 ElsevierInactivation of the 4-(Z)-Propenylproline Biosynthetic
Gene hrmD also Results in HRM A7 Formation
The unexpected metabolic phenotype observed for the DH
mutant raised new questions about the role of HrmH. Because
trans-(4-Me)Pro replaced (4-Pe)Pro in HRM A7, the biosynthesis
of (4-Pe)Pro was further investigated. Current knowledge
about this complex subpathway comes from functional analysis
of the HRM pathway and other routes that involve 4-alkyl-
substituted Pro building blocks and homologous genes, i.e.,
lincomycin and pyrrolo[1,4]benzodiazepine antibiotics (Peschke
et al., 1995; Hu et al., 2007; Li et al., 2009a, 2009b). All are initi-
ated by extradiol cleavage of L-DOPA, which is generated by
hydroxylation of L-tyrosine, and subsequent recyclization to
form an unstable pyrroline intermediate. In contrast to HrmH,
which is unique to the (4-Pe)Pro pathway, HrmD has close
homologs in the related pathways. The proteins are predicted
F420-dependent oxidoreductases likely involved in reducingLtd All rights reserved
Table 1. Bioassay of HRM andHRMAnalogs againstArthrobacter
crystallopoietes ATCC15481
HRM and HRM Analogs MIC (mg/ml)
HRM 0.001
HRM A1 0.01
HRM A2 0.01
HRM A3 0.001
HRM A4 0.1
HRM A5 1
HRM A6 1
HRM A7 0.001
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Regulation-Guided Formation of HRM Analogsand/or rearranging olefinic double bonds at a later stage of (4-Pe)
Pro biosynthesis (Ho¨fer et al., 2011). To investigate which influ-
ence the inactivation of a (4-Pe)Pro biosynthetic enzyme has
on HRM production, an insertional hrmD mutant (DD) was
created in a similar manner to DH. Fermentation of DD revealed
its role in HRM biosynthesis through complete abolishment of
HRM, while genetic complementation with hrmD restored HRM
production. Chemical complementation with (4-Pe)Pro also
restored production and thus confirmed the direct role of
HrmD in (4-Pe)Pro biosynthesis (Figure 4D). Instead of HRM,
the trans-(4-Me)Pro variant HRM A7 was detected in extracts
of DD fermentations. Upon addition of trans-(4-Me)Pro, the pro-
duction of HRM A7 increased in DD, paralleling the phenotypic
change in the DH strain. These observations show that, similar
to HrmD, HrmH influences the distributions of (4-Pe)Pro and
(4-Me)Pro in HRM biosynthesis, but in contrast to HrmD, is not
absolutely required for the production of (4-Pe)Pro.
The function of HrmH was further interrogated by studying the
biosynthetic origin of (4-Me)Pro. To test whether it is an interme-
diate/shunt product of the (4-Pe)Pro route or comes from a
different source, we fed a trideuterated form of the (4-Pe)Pro pre-
cursor L-DOPA [L-DOPA-(ring-d3)] into theWT andDH strains. As
expected, the label was successfully incorporated into HRM
(Figure S7) in both strains. In contrast, MS analysis revealed no
detectable labeling of HRM A7 in DH. This result suggests that
(4-Me)Pro is not an intermediate in (4-Pe)Pro biosynthesis but
rather originates from a source other than the HRM pathway.
To identify a possible (4-Me)Pro pathway, we searched the
available genome sequence (GenBank accession number:
NZ_GG657758.1) of the HRM producer for genes that might be
involved in (4-Me)Pro biosynthesis or incorporation; however,
no convincing gene candidate was identified.
Antibacterial Assays for HRM A1–A7
HRM and its analogs were tested at five different concentrations
against Arthrobacter crystallopoietes ATCC15481 in liquid-
based antimicrobial activity assays. The MIC (minimal inhibitory
concentration) values of these compounds are listed in Table 1.
All of the HRM analogs exhibit potent antibiotic activity against
the test strain. HRM A3 and HRM A7 have similar activity to
HRM, suggesting that there is structural tolerance of HRM’s
target for changes in the (4-Pe)Pro and endocyclic (3-Ncp)Ala
residues. In contrast, the exocyclic (3-Ncp)Ala moiety has a
stronger influence on activity, because HRM A4 and A5 lackingChemistry & Biology 20,this unit exhibit decreased potency. Similarly important, but
not absolutely required, seems to be the isoleucine residue
replaced in HRM A2. Finally, depending on their modification,
chlorinated pyrrole (Chpca) derivatives can have major or minor
influences on HRM activity (HRM A6 and A1).
DISCUSSION
To study the many unusual biosynthetic and biologic features of
HRM, the limitations of inconsistent and low production had to
be overcome. One aim of this study was therefore to exploit reg-
ulatory components in the HRMpathway tomodify titers through
metabolic engineering. Among the identified genes hrmA, hrmB,
and hrmH, individual overexpression of hrmA and hrmB resulted
in significant increases in HRM production, with a maximal in-
crease of 135-fold in the hrmB overexpression strain relative to
WT. In numerous growth experiments, strains exhibited excel-
lent stability. These results established HrmA and HrmB as
pathway-specific positive regulators for HRM biosynthesis.
The ability to significantly increase HRM production with trans-
acting plasmids provides an effective and reproducible platform
to study HRM biosynthesis in both WT and mutant strains.
A third gene, hrmH, was initially proposed to be a negative
regulator in HRM biosynthesis (Ho¨fer et al., 2011), yet disruption
of hrmH had no considerable effect on HRM production. The
peculiar phenotype observed with the DH strain, i.e., formation
of the additional congener HRM A7, allows for several possibil-
ities of HrmH’s role in HRM biosynthesis. Scenarios including
downregulation of trans-(4-Me)Pro biosynthesis, or upregulation
of (4-Pe)Pro biosynthesis are consistent with these data. It
should be taken into account that (4-Pe)Pro biosynthesis in
Streptomyces griseoflavus W-384 has not been fully elucidated
and that the HRM producer lacks a key enzyme present in
homologous pathways (Ho¨fer et al., 2011). All in all, our results
reveal HrmH influences product distributions and/or fidelity in
HRM biosynthesis. Defining the precise mechanism for HrmH
as transcriptional, translational, or small-molecule-mediated
regulation in S. griseoflavus W-384 will be the focus of future
studies.
The complexities of regulatory mechanisms involved in antibi-
otic biosynthesis, hallmarked by Streptomyces secondary meta-
bolism, are still poorly understood. Combined with our current
excess of genetic information encoding proteins that are largely
unverified and uncharacterized, manipulation of regulatory
genes within secondary metabolic clusters often have unfore-
seen consequences. Unexpected changes in the timing, produc-
tion, and metabolic profiles of secondary metabolites are often
reported (Wang et al., 2011; Stratigopoulos et al., 2002; Matsuno
et al., 2004; Gottelt et al., 2010; D’Alia et al., 2011; de la Fuente
et al., 2002). Even genes initially labeled to have biosynthetic or
unknown activities have been shown to harbor regulatory func-
tions (Volokhan et al., 2005; Hwang et al., 2003). Manipulation
of the previously proposed negative regulator hrmH revealed
HRM A7, which was shown to likely have (4-Pe)Pro replaced
with trans-(4-Me)Pro (Figures 4B and S5). Interestingly, the
source of trans-(4-Me)Pro remains undefined. The proposed
biosynthetic routes for (4-Pe)Pro biosynthesis do not include
trans-(4-Me)Pro as an intermediate (Ho¨fer et al., 2011). Previous
biochemical validation of the L-DOPA-cleaving activity of HrmF839–846, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 843
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Regulation-Guided Formation of HRM Analogsand its homolog in lincomycin biosynthesis did, however, highly
suggest L-DOPA as an early intermediate in (4-Pe)Pro biosyn-
thesis (Ho¨fer et al., 2011; Colabroy et al., 2008). Feedings of
deuterated L-DOPA in WT and DH cultures clearly showed
trans-(4-Me)Pro production was independent from (4-Pe)Pro
biosynthesis in S. griseoflavus W-384 (Figure S7). It should be
noted that free trans-(4-Me)Pro has been previously observed
in nature and therefore could be supplied by the complex
fermentation medium (Hulme and Arthington, 1954).
In addition to HRM A7, six HRM analogs (HRM A1–6) were
found through overexpression of hrmB in theWT strain (Figure 3),
of which HRM A6 is likely an artifact. Interestingly, HRM A7 was
not observed in any of the overproducing strains and only in
DH and DD. With the exception of HRM A1 and HRM A6, all of
the analogs had single or double substitutions with L-leucine
or L-valine. Recently, the specificities of all adenylation domains
(A domains) responsible for the activation and selection of amino
acids in the HRMNRPSs were probed using a g[18O4]-ATPmass
exchange assay (Cru¨semann et al., 2013; Phelan et al., 2009). In
disagreement with the leucine substitutions observed in HRM
A3–5, the A domains corresponding to the substituted positions
did not show high substrate tolerance for leucine. Moreover,
the A domain responsible for isoleucine incorporation in HRM re-
vealed in vitro selectivity for valine in these studies, correlating
with in silico predictions and the structure of the minor metabo-
lite HRM A2. Thus, unknown downstream constraints for resi-
dues incorporated into HRM might be present in this system.
Our data therefore highlight the potential benefits of in vivo
manipulation of regulatory genes over in vitro or in silico predic-
tions toward the production of accepted and bioactive NRPS-
derived natural product congeners.
Analogs HRMA1–6 also uncovered a previously unseen natural
plasticity in HRM biosynthesis and provided useful structure-
activity relationship (SAR) data that can aid in the design of
non-natural active analogs. Replacement of L-isoleucine with
L-valine had a modest 10-fold reduction in bactericidal activity
against A. crystallopoietes ATCC15481 (Table 1). Previous feed-
ings of various (3-Ncp)Ala analogs revealed flexible substrate
tolerances for these substitutions in HRM biosynthesis, while
often retaining partial antibiotic activity (Kozhushkov et al.,
2005; Zlatopolskiy et al., 2006). From these experiments, it was
hypothesized that terminal electron-withdrawing groups like
NO2 and CO2Me were necessary at these positions for incorpo-
ration into HRM. However, acceptance of L-leucine in place of
(3-Ncp)Ala in HRM A3–5 expands and refines the SARs and pro-
files of accepted amino acids in HRM determined in those
studies. Of note, HRM A3 retained full antimicrobial activity
compared to HRM, therefore revealing the D-configured
(3-Ncp)Ala unit flanked by (b-Me)Phe as an especially promising
candidate for future derivatization. Furthermore, our results sug-
gest that the epimerase domain of this module was able to
tolerate L-leucine and invert its configuration. Lastly, as seen
with HRM A6, previous experiments identified the N-hydroxy
group of Chpca as essential for HRM activity; however, the effect
of the chloro functionality remained unclear (Zlatopolskiy et al.,
2006). Our data show that the dechlorinated analog HRM A1 re-
tains potent, yet slightly reduced antibacterial activity compared
to HRM. With these insights, HRM residues that show flexibility
for incorporation with retention of activity can subsequently be844 Chemistry & Biology 20, 839–846, June 20, 2013 ª2013 Elseviermodified through mutasynthesis to act as ‘‘molecular handles’’
to pull down and identify HRM’s currently unknown cellular
target. Together with the significant increase in stable HRM
titers, research concerning HRM biosynthesis will be more trac-
table and tolerant to further manipulation and discovery.SIGNIFICANCE
In this study, we have identified two positive regulators,
HrmA and HrmB, in the hrm gene cluster via individual over-
expression in WT S. griseoflavus W-384. Six bioactive HRM
analogs were isolated and characterized from the HrmB
overproducer as a result of a 135-fold improvement in
HRM production. Additionally, we identified HrmH as a pro-
tein responsible for modulating HRM product distributions.
Fermentation of the hrmH-insertional mutant led to the
isolation of a seventh bioactive HRM analog. Antibiotic
assays with the seven congeners provided insights into
the structure-activity relationship and identified structural
positions that could permit the generation of active analogs
suitable for pull-down studies and target identification. This
research highlights the benefits of genetically engineering
regulatory elements in natural product gene clusters as an
effective and necessary tool for the exploitation and study
of secondary metabolites hampered by fermentative limita-
tions of the producing organism.EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, Primers, and Growth Conditions
Bacterial strains and plasmids used in this study are listed in Tables S3A and
S3B, respectively; primers are listed in Table S3C. Streptomyces griseoflavus
W-384 and its derivatives were grown either on solid GYMmedium containing
1% malt extract, 0.4% yeast extract, 0.4% glucose, 0.2% CaCO3 and 2%
Agar, adjusted pH to 7.2 at 30C for sporulation or in MMS liquid medium con-
taining 1% D-mannitol, 2% soybean flour, 2% meat extract, 0.02% NaCl, and
0.05% ZnSO4,7H2O (adjusted to pH 7.2) for isolation of genomic DNA
and fermentation for HRM production. Escherichia coli DH5a, BW25113,
and ET12567 were used for cloning and PCR-mediated recombination,
respectively (Gust et al., 2003). The pWEB-based (Epicenter) cosmid
pHR6G10 containing the hrm gene cluster from hrmA to part of hrmO was
used for gene replacement of hrmH and hrmD. For transformant selection,
the following antibiotics were used: carbencillin (100 mg/ml), apramycin
(50 mg/ml), and kanamycin (50 mg/ml) for E. coli; and apramycin (25 mg/ml)
and thiopstrepton (12.5 mg/ml) for Streptomyces. Procedures of DNA isolation
and manipulation in E. coli and Streptomyces are described elsewhere (Kieser
et al., 2000; Sambrook, 2001).
Construction of HRM Overproducers
For clone selection, the apramycin resistance genewas amplified by PCR from
pIJ773 using primers XF9F/9R. The resulting purified PCR product was then
cut with ClaI and EcoRV and ligated into the same sites in pWHM4* to obtain
pXC10, a Streptomyces autoreplicating expression vector. Genes hrmA and
hrmB were amplified from S. griseoflavus W-384 genomic DNA using primers
XF10F/10R and XF11F/11R and cloned into pBluescript SK-II(+) to give pXC11
and pXC12, respectively. The sequence-verified hrmA and hrmB fragments
were then digested from pXC11 and pXC12 and individually ligated into
pXC10 in front of the constitutive Streptomyces promoter ermE* (Bibb et al.,
1985) to obtain pXC14 and pXC13. The resulting plasmids were separately
introduced into themethylation-deficient strain E. coli ET12567 and then trans-
formed intoS. griseoflavusW-384 by PEG-mediated protoplast transformation
according to standard procedures (Kieser et al., 2000) to yield the desired
overproducing strains.Ltd All rights reserved
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A 1.4 kb fragment containing the apramycin resistance cassette amplified from
pIJ773 using primers XF18F/18R was used to disrupt hrmH in pHR6G10. The
resulting cosmid was then used to generate theDHmutant via a PCR-targeting
system (Gust et al., 2003). The mutant was confirmed by PCR amplification
using primer pairs XF26F/29R, XF29F/26R, and XF29F/19R. For genetic
complementation of DH, the hrmH gene fragment amplified from genomic
DNA of S. griseoflavus W-384 using primers XF24F/24R was first inserted
into pBluescript SK-II(+) to give pXC19. After sequence verification, the correct
hrmH gene fragment was digested from pXC19 and ligated into pWHM4* to
obtain pXC26. Finally, nonmethylated pXC26was introduced into theDH strain
to generate the DH complement DH/HrmH.
Fermentation, Extraction, and Analysis of HRM-RelatedMetabolites
Ten microliters of spore suspension (1 3 108 spores/ml) was inoculated into
10 ml MMS media supplemented with the appropriate antibiotic and shaken
for 2 days at 27C at 250 rpm. Fivemilliliters of this culture was then transferred
into 45ml MMSmedia in 250ml flasks baffled with springs (production culture)
and grown for 5 more days. For isolation of HRM analogs, 800 ml of total
production culture was obtained by cultivation of the above small-scale fer-
mentations in parallel in 16 flasks with 50 ml of medium each because HRM
production in a larger scale was respectively much lower. After fermentation,
the culture supernatant was collected after centrifugation, extracted three
times with equal volumes of ethyl acetate, dried via evaporation, and dissolved
in methanol. Methanol extracts were analyzed on a Jasco HPLC system or
Bruker Daltonics LC-MS using a reverse-phase column (KNAUER Eurospher
II 100-5 RP C-18, 5 mm, 4.0 mm3 250 mm) with an isocratic method of aceto-
nitrile (75%) and dH2O with 0.1% TFA (v/v) (25%) for 50 min at 1.0 ml/min. The
detection wavelength was 273 nm. The retention times of HRM and HRM
derivatives (HRM A1–A7) are 7.2 min (HRM A7), 10.2 min (HRM A1 and HRM
A2), 13.4 min (HRM), 20.3 min (HRM A3 and HRM A4), 23.4 min (HRM A5),
and 38.5 min (HRM A6).
Feeding Studies and Chemical Complementation of Mutants
All the strains related to S. griseoflavus W-384 were fed with different precur-
sors, including (4-Pe)Pro and (3-Ncp)Ala, L-pipecolic acid (Sigma Aldrich), and
trans-(4-Me)Pro (Key Organics) during fermentation. Compounds (4-Pe)Pro
and (3-Ncp)Ala were synthesized as previously described (Zlatopolskiy and
de Meijere 2004; Zlatopolskiy et al., 2004; Kozhushkov et al., 2005). After
2-day seed culture cultivation, production cultures were inoculated and imme-
diately fed the above individual amino acids. During 3 days of growth in
production medium, the amino acids were added every 12 hr for a total of
five times with a final concentration of 0.3 mg/ml. Extraction of HRM and its
derivatives followed as described previously.
MS and NMR Analysis of HRM Analogs
High-resolution ESI-MS spectra were performed on a Thermo LTQOrbitrap XL
mass spectrometer, running Xcalibur 2.1.0 software. The spectra were re-
corded by infusion into the ESI source using MeOH as the solvent. The instru-
ment was first autotuned on the m/z value of the ion to be fragmented. Then,
the [M+H]+ ion of each compound was isolated in the linear ion trap and frag-
mented by CID. Sets of consecutive, high-resolution, full MS/MS scans were
acquired in centroid or profile mode and analyzed using the QualBrowser soft-
ware (Thermo). NMR spectra were acquired on a Varian Unity Inova spectrom-
eter at 700 MHz; chemical shifts were referenced to the residual solvent signal
(CD3OD: dH 3.31). For an accuratemeasurement of the coupling constants, the
one-dimensional 1H NMR spectra were transformed at 64K points (digital
resolution: 0.09 Hz). HPLC separations were achieved on a Varian Prostar
210 apparatus equipped with a Prostar 325 UV-Vis detector.
Bioactivity Assays
The detection of HRM and its derivatives was prepared by applying 20 ml of
culture supernatant to paper discs on solid Luria broth medium (LB) impreg-
nated with Arthrobacter crystallopoietes as the test strain. The inhibition zones
were observed after plate incubation at 30C overnight (Figure S3). To
determine the MICs of HRM and its analogs, 1, 0.1, 0.01, 0.001, and
0.0001 mg/ml dilutions of the compounds (final concentration) were added toChemistry & Biology 20,Arthrobacter crystallopoietes liquid cultures in 5 ml of LB and shaken at
30C overnight to monitor for cell growth.
Methanolysis of HRM and HRM A7
Less than 1 mg of HRM or HRM A7, dissolved in 100 ml of methanol, was dried
and redissolved in 15 ml MeOH before the addition of 10 ml of sodium methox-
ide and incubation at room temperature overnight. The mixture was then par-
titioned between H2O (750 ml) and ethyl acetate (750 ml 3 3), the ethyl acetate
fractions were dried, and the resulting peptide fragments were analyzed with
ESI-MS/MS.
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